We are dedicated to
finding, developing, and commercializing innovative products for the unmet medical needs of patients suffering from central nervous system diseases and injuries.
NeuroAiD (MLC901)
Clinical research continues to expand the evidence on NeuroAiD across neurological conditions.
- =Moleac’s first product, with clinical research spanning post-stroke and post-traumatic brain injury recovery, as well as cognitive disorders.
- =Supported by an extensive body of preclinical, clinical, and real-world evidence on its pharmacology, efficacy, and safety.
- =Ongoing and planned clinical research continues to further characterize the use of NeuroAiD across these neurological conditions.
- =Real-world evidence and post-marketing research are supported by the NeST Registry, an ongoing international, multi-indication registry evaluating the use of NeuroAiD in routine clinical practice.
MLC1501
- MLC1501 is a botanical product under development for neurologic conditions, with 3 INDs (Investigational New Drug) applications open with the US FDA for stroke, traumatic brain injury and Alzheimer’s disease. It is currently completing phase II development.
Ongoing clinical trials
Clinicaltrials.gov link –NCT04766281
Protocol Title – Safety and Efficacy of MLC901 (NeuroAiD II) in Patients with Moderate TBI: A Randomized Double-Blind Placebo Controlled Trial
Indication – Moderate Traumatic Brain injury
Recruitment status – Recruiting
Phase – 4
Location – Philippines
Clinicaltrials.gov link –NCT07191028
Protocol Title – A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of MLC901 (NeuroAiD™II) in subjects with mild to moderate Alzheimer’s Disease (AD).
Indication – Mild to moderate AD
Recruitment status – Not yet recruiting
Phase – III
Location – Singapore, Malaysia and the Philippines
